Skip to main content
. Author manuscript; available in PMC: 2014 Nov 12.
Published in final edited form as: Biochem J. 2014 Apr 1;459(1):229–239. doi: 10.1042/BJ20131099

Scheme 1.

Scheme 1

Schematic representation of preparation of fluorophore-labeled FXa. FX was first labeled with donor (Alexa Fluor 555 succinimidyl ester; A555-NHS) followed by activation to remove the activation peptide at its N-terminus. The acceptor (fluorescein-labeled EGR-chloromethylketone; FEGRck) was then added to the active site of A555-Xa to produce doubly labeled peptide or to FXa to produce singly labeled peptide.